ImetelChat

is there anyone who has looked at the ARGX MDS trial that doesn't think that this is why JNJ dropped imet?

https://www.argenx.com/en-GB/news-inter ... mia/30208/

So the question now is which direction GERN should go.

Argx drug targets high risk MDS whereas Imet targets intermediate-1 or low risk patient groups. However, phenomonal success of their drug in AML may be a significant threat to Geron's future attempt to widen the scope of treatment space to include AML.